Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
West Pharmaceutical ServicesWST +0.63%95 EV-to-OCF is 35.90 as of Jul. 31, 2026, which is 14% above its 10-year median of 31.47. GuruFocus rates WST with a GF Score™ of 95/100 and a GF Value™ of $356.12 (Fairly Valued). The stock has 8 warning signs investors should review. Among 852 Medical Devices & Instruments companies, West Pharmaceutical Services ranks worse than 87.56% on this metric.
The historical rank and industry rank for West Pharmaceutical Services's EV-to-OCF or its related term are showing as below:
WST'
s EV-to-OCF Range Over the Past 10 Years
Min: 21.64 Med: 31.47 Max: 69.74
Current: 35.9
During the past 13 years, the highest EV-to-OCF of West Pharmaceutical Services was 69.74. The lowest was 21.64. And the median was 31.47.
WST's EV-to-OCF is ranked worse than 87.56% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 7.865
vs WST: 35.90
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
West Pharmaceutical Services (NYSE:WST) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
West Pharmaceutical Services's PE Ratio (TTM) for today is calculated as:
West Pharmaceutical Services's share price for today is $339.59.
West Pharmaceutical Services's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.810.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
West Pharmaceutical Services EV-to-OCF Related Terms
West Pharmaceutical Services EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
West Pharmaceutical Services EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where West Pharmaceutical Services's EV-to-OCF falls into.
West Pharmaceutical Services's current Enterprise Value is $23,775 Mil.
West Pharmaceutical Services's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $662 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
West Pharmaceutical Services (WST) has a EV-to-OCF of 35.90 as of Jul. 31, 2026. This is 14% above median its historical median of 31.47. Over the past decade, West Pharmaceutical Services' EV-to-OCF has ranged from 21.64 to 69.74. According to the industry distribution chart, West Pharmaceutical Services ranks #746 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 87.6%.
Is West Pharmaceutical Services' EV-to-OCF too high?
West Pharmaceutical Services' current EV-to-OCF of 35.90 is 14% above median its 10-year median of 31.47. Over the past 10 years, this metric has ranged from a low of 21.64 to a high of 69.74. The Medical Devices & Instruments industry median EV-to-OCF is 7.87. West Pharmaceutical Services' value of 35.90 is 356.5% above this industry median. Based on the distribution chart, West Pharmaceutical Services ranks #746 out of 852 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, West Pharmaceutical Services has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does West Pharmaceutical Services' EV-to-OCF compare to RMD and COO?
According to the Medical Devices & Instruments industry distribution chart, West Pharmaceutical Services ranks #746 out of 852 companies for EV-to-OCF. This places West Pharmaceutical Services in the lower half of its industry. The industry median EV-to-OCF is 7.87. West Pharmaceutical Services' value of 35.90 is 356.5% above this benchmark. Historically, West Pharmaceutical Services' own EV-to-OCF has ranged from 21.64 to 69.74 over the past decade. While the company's 10-year median is 31.47 vs. the industry median of 7.87, West Pharmaceutical Services has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.87, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. West Pharmaceutical Services's current EV-to-OCF of 35.90 is 356.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. West Pharmaceutical Services's current EV-to-OCF is 35.90, which is 14% above median its own 10-year median of 31.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is West Pharmaceutical Services stock overvalued right now?
Based on GuruFocus' analysis, West Pharmaceutical Services (WST) is currently considered Fairly Valued. The stock's GF Value™ is $356.12, compared to a current price of $339.59 — trading 4.6% below its estimated fair value. The current EV-to-OCF is 35.90, which is 14% above median its 10-year median of 31.47 and 356.5% above the Medical Devices & Instruments industry median of 7.87. West Pharmaceutical Services' overall GF Score™ is 95/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For West Pharmaceutical Services (WST), the current EV-to-OCF is 35.90 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is West Pharmaceutical Services (WST) Overvalued in 2026?
Based on GuruFocus' analysis, West Pharmaceutical Services stock appears to be undervalued.
The current stock price of $339.59 is trading 4.6% below its estimated GF Value™ of $356.12.
GuruFocus considers West Pharmaceutical Services to be Fairly Valued.
Key valuation signals for WST:
EV-to-OCF: 35.90 (14% above median its 10-year median of 31.47)
GF Value™: $356.12 vs. price of $339.59 (4.6% below fair value)
Industry Position: 356.5% above the Medical Devices & Instruments median (#746 of 852)
No single metric tells the full story. See the WST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
95GF Score
Get the complete analysis for WST
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WST has been successfully added to your 
